Tissue Resources and Molecular Pathology

组织资源和分子病理学

• 批准号: 8747070
• 负责人: IGNACIO I. WISTUBA
• 金额: $ 23.99万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-09-30 至 2019-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8747070
• 关键词: B-Lymphocytes; Basic Science; Belief; Bioinformatics; Biological Assay; Biometry; Blood Banks; Blood Cells; Blood specimen; Cancer Center; Cancer cell line; Cataloging; Catalogs; Cell Line; Cells; Clinical; Clinical Data; Clinical Research; Clinical Trials; Collaborations; Collection; Colorado; Complement; DNA; Data; Development; Drug or chemical Tissue Distribution; Epithelial Cells; Funding; Grant; Guidelines; Institution; Investigation; Lung; Malignant - descriptor; Malignant neoplasm of lung; Medicine; Methodology; Molecular; Mutation; Non-Malignant; Non-Small-Cell Lung Carcinoma; Outcome; Paraffin; Pathogenesis; Pathologic; Pathology; Patients; Peer Review; Play; Positioning Attribute; Process; Proteins; Publications; RNA; Reagent; Research; Research Activity; Research Personnel; Research Project Grants; Resources; Role; Sampling; Services; Site; Specimen; Surgical Pathology; Testing; Tissue Banking; Tissue Banks; Tissue Microarray; Tissue Procurements; Tissues; Translational Research; Tumor Cell Line; United States National Institutes of Health; Xenograft procedure; Yale Cancer Center; base; biobank; cell bank; clinical application; data sharing; genome-wide; high standard; innovation; molecular pathology; novel; programs; success; tissue processing; tissue resource; tumor

The Pathology and Tissue Resources Core will provide routine and innovative tissue resources and materials essential for achieving the aims of the SPORE projects. Routine materials include tumors and non-malignant lung specimens and tumor cell lines. Over 3,000 tumors and 300 lung cancer cell lines have been banked, and over 50,000 aliqouts of tumor or cell line pellets, RNA or DNA or paraffin sections have been distributed to investigators. Our Aim 1 is to collect, process, store, catalog and distribute tissues, cell lines and blood specimens, both malignant and nonmalignant, and relevant clinico-pathologic and molecular data, as requested by the various component projects of the SPORE program. Aim 2 is to develop and utilize innovative and routine tissue and cell line resources that will aid in the successful completion of the SPORE program aims. These include development of new tumor cell line resources to complement recent genome wide mutation data on lung cancer oncogenotypes. Aim 3 is to perform and interpret tissue-based molecular methodologies in close collaboration with the component projects of the SPORE program to satisfy their approved aims. This will involve developing molecular assays that eventually can be deployed as CLIA certified lab tests to facilitate the planned translational science clinical trials in most of the SPORE projects. This Core will play a crucial role on promoting collaboration among our own SPORE investigators, investigators at other Lung Cancer SPORE sites, and investigators at our own and other institutions including other peer-reviewed projects funded by NCI/NIH and other agencies. All of our SPORE projects will utilize Core B materials and services. Heavy utilization of our routine and innovative materials, and close interactions with the SPORE investigators will greatly aid the successful completion of the aims of our SPORE proposal.

病理学和组织资源核心将提供常规和创新的组织资源和材料，对实现孢子项目的目标至关重要。常规材料包括肿瘤和非恶性肺标本及肿瘤细胞株。超过3,000个肿瘤和300个肺癌细胞系已被储存，超过50,000份肿瘤或细胞系颗粒、RNA或DNA或石蜡切片已分发给调查人员。我们的目标1是根据孢子计划的各个组成部分项目的要求，收集、处理、存储、编目和分发组织、细胞系和血液标本，包括恶性和非恶性的，以及相关的临床病理和分子数据。目标2是开发和利用创新和常规的组织和细胞系资源，这将有助于成功完成孢子计划的目标。这些措施包括开发新的肿瘤细胞系资源，以补充最近关于肺癌癌基因类型的全基因组突变数据。目标3是与孢子计划的组成部分项目密切合作，执行和解释基于组织的分子方法，以满足其批准的目标。这将涉及开发分子分析，最终可以作为CLIA认证的实验室测试来部署，以促进大多数孢子项目中计划的转化科学临床试验。这个核心将在促进我们自己的孢子调查人员、其他肺癌孢子站点的调查人员以及我们自己和其他机构的调查人员之间的合作方面发挥关键作用，包括由NCI/NIH和其他机构资助的其他同行评审项目。我们所有的孢子项目都将使用核心B材料和服务。大量使用我们的常规和创新材料，以及与孢子调查人员的密切互动，将极大地帮助我们成功完成孢子提案的目标。